INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP), Pennsylvania, Plymouth Meeting Beloud

@wfmz.com · 58 minutes

BREAKING NEWS

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

The FDA has granted accelerated approval to INOVIO's VOCERYQ, a DNA-based immunotherapy designed to reduce the frequency of surgery in adults suffering from recurrent respiratory papillomato...

Read more Wfmz.com